Phase II Study of Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in Patients With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
Summary
The purpose of this phase II study is to investigate if nivolumab given with tadalafil and vancomycin causes liver cancer to shrink.
General Information
NCT#: NCT03785210
Study ID: 190033
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Tadalafil, Nivolumab, Vancomycin